Австралия - английски - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 5 microgram - injection, suspension - excipient ingredients: aluminium; water for injections; sodium chloride; borax - for use in the immunisation against infection caused by all known subtypes of hepatitis b virus. indications as at 17 november 2000: h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who are at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

Малта - английски - Medicines Authority

lg life sciences poland sp.z.o.o. ui. grzybowska 80/82, 00-844 warsaw, poland - hepatitis b, surface antigen, hbs ag - suspension for injection - hepatitis b surface antigen (hbs ag) 20 µg - vaccines

Малта - английски - Medicines Authority

lg life sciences poland sp.z.o.o. ui. grzybowska 80/82, 00-844 warsaw, poland - hepatitis b, surface antigen, hbs ag - suspension for injection - hepatitis b surface antigen (hbs ag) 10 µg - vaccines

Малта - английски - Medicines Authority

nm pharma limited 3/4, cantrija complex triq it-targa, il-maghtab naxxar nxr 6613 , malta - hepatitis b, surface antigen, hbs ag - suspension for injection in pre-filled syringe - hepatitis b surface antigen (hbs ag) 20 µg/ml - vaccines

Малта - английски - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - hepatitis b, surface antigen, hbs ag, aluminium hydroxide, hydrated - suspension for injection - hepatitis b surface antigen (hbs ag) 20 µg/ml aluminium hydroxide, hydrated 0.5 µg/ml - vaccines

Европейски съюз - английски - EMA (European Medicines Agency)

dynavax gmbh - hepatitis b surface antigen - hepatitis b - vaccines - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations.it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

beckman coulter australia pty ltd - 48321 - hepatitis b virus surface antigen ivd, kit, chemiluminescent immunoassay - paramagnetic particle, chemiluminescent immunoassay for qualitative detection of surface antigen hepatitis b virus hbs ag the access hbs ag assay is a paramagnetic particle, chemiluminescent immunoassay for the qualitative detection of the surface antigen of the hepatitis b virus (hbs ag) in human serum and plasma using the access immunoassay systems.

САЩ - английски - NLM (National Library of Medicine)

merck sharp & dohme corp. - hepatitis b virus subtype adw hbsag surface protein antigen (unii: xl4hlc6jh6) (hepatitis b virus subtype adw hbsag surface protein antigen - unii:xl4hlc6jh6) - hepatitis b virus subtype adw hbsag surface protein antigen 1 g in 1 g

Австралия - английски - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - 48321 - hepatitis b virus surface antigen ivd, kit, chemiluminescent immunoassay - the atellica im hbsii conf assay uses the principle of specific antibody neutralisation to confirm the presence of hbsag in a sample that is repeatedly reactive for hbsag. an in vitro diagnostic immunoassay for the qualitative confirmation of the presence of hepatitis b surface antigen (hbsag) in human serum or plasma (edta, lithium or sodium heparin, citrate). the assay is intended to be used to confirm the presence of hbsag in samples that are repeatedly reactive.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

siemens healthcare pty ltd - 48321 - hepatitis b virus surface antigen ivd, kit, chemiluminescent immunoassay - the atellica im hbsii assay is a sandwich immunoassay using direct chemiluminometric technology. an in vitro diagnostic immunoassay for the qualitative detection of hepatitis b surface antigen (hbsag) in human serum and plasma (edta, lithium heparin, sodium heparin, sodium citrate). the assay may be used in conjunction with other serological and clinical information to diagnose individuals with acute or chronic hepatitis b infection. the assay may also be used to screen for hepatitis b infection in pregnant women to identify neonates who are at risk of acquiring hepatitis b during the perinatal period.